WINTHROP, MA, November 16, 2026 /24-7PressRelease/ -- Nirjhar Chatterjee, MD, has been recognized by Marquis Who's Who for his achievements in pharmacovigilance, global patient safety, medical affairs and clinical development.
Dr. Chatterjee has established himself as an accomplished pharmaceutical physician and global patient safety leader, dedicating more than three decades to advancing the development and safe use of medicines. Since 2026, he has served as the owner of Poseidon Core Pharma Consulting LLC, providing strategic medical and scientific expertise to biotechnology and pharmaceutical companies. His work encompasses preclinical and clinical safety assessments, evaluation of emerging safety signals, product safety labelling, benefit–risk assessments and the presentation of medical recommendations to corporate safety review boards. Throughout his career, Dr. Chatterjee has maintained that patient welfare must remain at the centre of every decision concerning the development, approval and continued use of medicines.
His expertise extends across small-molecule therapeutics, recombinant and plasma-derived proteins, enzyme therapies, immunology and treatments for inherited bleeding disorders, including haemophilia A and B and von Willebrand disease.
Dr. Chatterjee held a senior medical leadership position in Global Patient Safety and Pharmacovigilance of small molecules at Crinetics Pharmaceuticals. Previously, he held positions of increasing responsibility in pharmacovigilance, patient safety and medical affairs at Baxter, Baxalta, Shire and Takeda, organisations connected through successive mergers and acquisitions. Throughout his tenure with these companies, he contributed to global drug safety strategy, clinical development, benefit–risk assessment and regulatory activities, with particular expertise in rare diseases, inherited bleeding disorders and other complex therapeutic areas.
His extensive international experience also encompasses senior Global Medical Affairs roles at Novartis Vaccines and GlaxoSmithKline (GSK) Vaccines, where he contributed to the scientific and medical strategies supporting vaccine development. Earlier, Dr. Chatterjee spent several years at UCB Pharma in Belgium, where his responsibilities included research involving peptides, and medical affairs activities across multiple therapeutic areas.
Before entering the pharmaceutical industry, Dr. Chatterjee pursued an academic research career at the National Institute of Immunology, New Delhi, India, conducting research involving peptides and their potential applications in vaccine development. This early scientific foundation, combined with subsequent leadership responsibilities across major international pharmaceutical organisations, has shaped his multidisciplinary approach to medicine, integrating scientific discovery, clinical development, medical affairs and patient safety.
Dr. Chatterjee attributes much of his professional philosophy to the rigorous academic foundations established during his education. He attended St. Xavier's School in Delhi, India, where Jesuit educators instilled the values of intellectual discipline, ethical responsibility and service to others. He subsequently completed his Doctor of Medicine qualification at the University of Delhi and pursued further postgraduate medical studies at universities in Belgium. These educational experiences shaped his approach to medical decision-making, particularly when confronting complex clinical situations involving uncertainty, incomplete evidence and difficult benefit–risk judgments. His guiding principle has remained consistent: patient welfare must always take precedence.
Beyond his professional responsibilities, Dr. Chatterjee actively supports animal welfare organisations and charitable initiatives benefiting rural communities in India. His philanthropic interests reflect a lifelong belief in compassion, social responsibility and the importance of contributing to communities across geographical boundaries.
Dr. Chatterjee's professional and personal journey has taken him across India, West Africa, Europe and the United States. His experiences in Chicago and Boston have further shaped his philosophy of collaborative leadership. Drawing inspiration from American football, he believes that success depends not only on the individual carrying the ball but also on teammates protecting that individual's blind side and enabling the entire team to advance toward a common goal. Similarly, his appreciation of sailing reinforces the principle that, when circumstances become challenging, everyone must contribute — all hands on deck. For Dr. Chatterjee, effective leadership is grounded in mutual respect, shared accountability and the conviction that no individual is more important than the collective mission.
Two particularly memorable clinical experiences illustrate Dr. Chatterjee's dedication to patient safety and compassionate medical decision-making.
The first occurred during his work with plasma-derived clotting factor products. After receiving information from a physician in Australia concerning a critically ill patient in an intensive care unit, Dr. Chatterjee recognised that the clinical circumstances revealed important new safety evidence that warranted reconsideration of the product's existing labelling. Rather than waiting for additional similar reports, he initiated the process of reassessing the available evidence and updating the product safety information. The experience reinforced his belief that a single well-documented clinical case can provide meaningful evidence of an important safety risk and that protecting patients sometimes requires decisive action before a pattern of adverse events becomes apparent.
A second defining experience arose during the clinical development of an investigational peptide therapy for a rare inherited bleeding disorder. A physician in the United Kingdom approached Dr. Chatterjee regarding a critically ill patient in an intensive care unit who was not responding to established standards of care. Tragically, the patient had previously lost two brothers to the same genetic disorder. Although the patient's clinical circumstances fell outside the population originally planned for the study, Dr. Chatterjee recognised the exceptional medical need and supported the treating physician in pursuing compassionate access to the investigational medicine. The intervention was successful and saved the patient's life.
These experiences remain among the most meaningful achievements of Dr. Chatterjee's career. They embody his conviction that pharmaceutical medicine is ultimately about protecting individual human lives, and that scientific knowledge must be accompanied by ethical judgment, compassion and the willingness to act responsibly in difficult circumstances.
Throughout his distinguished international career, Dr. Chatterjee has remained committed to scientific rigour, ethical responsibility and the advancement of patient-centred pharmaceutical medicine. Looking ahead, he intends to expand his consulting activities through Poseidon Core Pharma Consulting LLC, supporting biotechnology and pharmaceutical companies in clinical development, global patient safety, medical affairs and regulatory strategies.
Dr. Chatterjee also envisions a future in which artificial intelligence and advanced data analytics accelerate the identification of emerging safety signals, strengthen benefit–risk assessments, improve the interpretation of complex clinical evidence and facilitate the development of innovative treatments, particularly for patients with rare diseases.
While recognising the transformative potential of these technologies, he maintains that artificial intelligence must enhance rather than replace the scientific judgment, clinical experience and ethical responsibility of physicians.
For Dr. Chatterjee, technological advancement is meaningful only when it contributes to better medical decisions and improved outcomes for patients.
His enduring professional philosophy is that regulatory compliance establishes the foundation of pharmaceutical medicine, while genuine patient centricity defines its highest purpose.
# # #
Contact Information
Email: Email Us Here